Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer
Jessica Armand(Columbia University Irving Medical Center), Hee Won Yang(Columbia University Irving Medical Center)
Cited by 0
Related Papers
Locally excitable Cdc42 signals steer cells during chemotaxis
|Nature Cell Biology|2015|189
Stress-mediated exit to quiescence restricted by increasing persistence in CDK4/6 activation
|eLife|2020|95
CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition
|Scientific Reports|2022|93
Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer
|Cell Reports|2023|54
Non-canonical pathway for Rb inactivation and external signaling coordinate cell-cycle entry without CDK4/6 activity
|Nature Communications|2023|34